New cholera pill tested in sweden – first human study begins
NCT ID NCT07270796
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new oral cholera vaccine called DuoChol in 60 healthy adults aged 18 to 45 in Sweden. Participants will receive two doses of either DuoChol or an existing vaccine (Dukoral) to compare safety and immune response. The goal is to gather initial data to support future studies in areas where cholera is common.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLERA VACCINATION REACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Studieenheten Akademiskt Specialistcentrum
Stockholm, Sweden
Contact Email: •••••@•••••
Contact